Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 3:50 AM ET

Sponsor Check › Person

Brian Strem

Named as an officer, director or promoter on SEC Form D filings · CA, MA, TX · Dec 29, 2017 → Apr 21, 2026

2deals (issuers)

$21.2Mreported sold

50investors

9Form D filings

2017–2026years on file

Follow this person Look further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:40 AM ET · SEC enforcement last checked: not yet

The short version

Brian Strem is listed as an executive officer, director, and promoter on 9 SEC Form D filings by 2 issuers between Dec 2017 and Apr 2026: KIORA PHARMACEUTICALS INC (Encinitas, CA — pharmaceuticals — 2021–2026; $15M reported sold to 32 investors) and Okogen, Inc. (Plano, TX — industry reported as "Other" — 2017–2024; $6.19M reported sold to 18 investors).

What this means 2 separate companies raised money with this person listed as executive officer, director, and promoter, over about 9 years. Across those companies the filings report $21.2M sold in total.

Listed alongside Eric Daniels (7 shared filings), Aron Shapiro (6 shared filings), Praveen Tyle (6 shared filings), Kenneth Gayron (5 shared filings), David Hollander (4 shared filings) and 13 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Brian. Each name links to their own page.

1 of the issuers belongs to the sponsor group Okogen (2 issuers, $2.45M reported sold, 2017–2024).

What this means A sponsor group is one team that sets up a new company for each deal. Okogen has 2 companies on file and $2.45M reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), state securities regulators (AZ, CA, DE, TX, WA) — 1 bankruptcy case matching the name listed in Key records below. Not yet searched: SEC enforcement releases.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

What the community is saying

Nothing found on Reddit, BiggerPockets or community forums for high-net-worth investors (searched Oct 24, 2026) — search queued; this line updates when it has run.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 2:40 AM ET.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

Not yet searched

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched.

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.

No SEC search has run yet for this person.

3. Bankruptcies

1 case: 1 closed (disposition not in docket feed)

FAR EAST NATIONAL BANK v. Strem closed

United States Bankruptcy Court, C.D. California · No. 1:09-ap-01163 · Filed May 26, 2009 · Closed Apr 20, 2010

Role of Strem: Defendant · Outcome: Case closed 2010-04-20 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗

same rare surname (3 people in Form D filings, 4 federal dockets); surname only in the caption; court in the person's filing state (CA)

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:40 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

4. Differences between public sources

Not made for individual people — comparisons cover issuers and sponsor groups

5. Money to insiders

2 of 9 offerings report sales commissions totalling $1,910,001; 1 reports finder's fees totalling $3,274; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)

Offering (latest filing)	Sales commissions	Finder's fees	To insiders	Paid to sell it	Source
Apr 21, 2026 D KIORA PHARMACEUTICALS INC File 021-581327	$0	$0	$0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.	None listed on this filing	EDGAR ↗
Dec 12, 2024 D Okogen, Inc. File 021-531857	$0	$0	$0	None listed on this filing	EDGAR ↗
Feb 14, 2024 D KIORA PHARMACEUTICALS INC File 021-505316	$1,050,000	$0	$0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.	Maxim Group LLC BrokerCheck CRD 120708 ↗	EDGAR ↗
Jan 9, 2024 D Okogen, Inc. File 021-501943	$0	$0	$0	None listed on this filing	EDGAR ↗
Feb 17, 2023 D KIORA PHARMACEUTICALS INC File 021-473809	$0	$0	$0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.	None listed on this filing	EDGAR ↗
Feb 17, 2023 D KIORA PHARMACEUTICALS INC File 021-473810	$0	$0	$0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.	None listed on this filing	EDGAR ↗
Nov 4, 2021 D KIORA PHARMACEUTICALS INC File 021-419911	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 23, 2021 D KIORA PHARMACEUTICALS INC File 021-410958	$860,001	$0	$0 Some of the proceeds may be used for working captial and other general corporate purposes, which may include the payment of salaries and other fees to those listed in item 3.	H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗	EDGAR ↗
Dec 29, 2017 D Okogen, Inc. File 021-302024	$0	$3,274 (est.)	$0	Marc Gleeson no CRD number reported	EDGAR ↗

How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 2

Every issuer that named Brian Strem on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

Pharmaceuticals

KIORA PHARMACEUTICALS INC

Encinitas, CA · Aug 23, 2021 → Apr 21, 2026 · 6 filings

Apr 21, 2026 · D · $5,000,000 sold of $5,000,000 · 3 investors · min. No minimum reported · role: Executive Officer (President and Chief Executive Officer) EDGAR ↗
Feb 14, 2024 · D · $15,000,000 sold of $15,000,000 · 13 investors · min. No minimum reported · role: Executive Officer (President and Chief Executive Officer) EDGAR ↗
Feb 17, 2023 · D · $200,000 sold of $200,000 · 1 investors · min. No minimum reported · role: Executive Officer, Director (President and Chief Executive Officer) EDGAR ↗
Feb 17, 2023 · D · $0 sold of $10,000,000 · 1 investors · min. No minimum reported · role: Executive Officer, Director (President and Chief Executive Officer) EDGAR ↗
Nov 4, 2021 · D · $67,258 sold of Indefinite · 6 investors · min. No minimum reported · role: Executive Officer, Director (President and Chief Executive Officer) EDGAR ↗
Aug 23, 2021 · D · $10,750,013 sold of $10,750,013 · 14 investors · min. No minimum reported · role: Executive Officer, Director (President and Chief Executive Officer) EDGAR ↗

Raised $15M from 32 investors (100% of the $5M target) as of the latest filing. Brian is listed as executive officer, director on 6 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other · group: Okogen

Okogen, Inc.

Plano, TX · Dec 29, 2017 → Dec 12, 2024 · 3 filings

Dec 12, 2024 · D · $2,451,332 sold of $2,800,000 · 9 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗
Jan 9, 2024 · D · $213,020 sold of $594,253 · 4 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
Dec 29, 2017 · D · $6,193,492 sold of $6,193,492 · 18 investors · min. No minimum reported · role: Executive Officer, Director, Promoter EDGAR ↗

Raised $6.19M from 18 investors (100% of the $2.8M target) as of the latest filing. Brian is listed as director, promoter, executive officer on 3 filings for this deal.

Latest filing on EDGAR ↗

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

People around Brian 18

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET.

Person